Aghaegbulam Uga, MD
Psychiatry · El Paso, TXNPI 1083925945
Payments from drug & device makers
Across 579 payments — averaging $301.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$67K
- Johnson & Johnson$53K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$22K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$11K
- AbbVie$9K
- H. Lundbeck A S$6K
- plus $7K from 19 others
What the payments were for
- Consulting fees$5,3946%
- Speaking & faculty fees$66,34371%
- Travel & lodging$8,6059%
- Food & beverage$12,81214%
- Education$2930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 83 | $66,612 |
| Johnson & Johnson | 127 | $53,427 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $21,541 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $10,834 |
| AbbVie(2 entities) | 62 | $9,320 |
| H. Lundbeck A S | 6 | $5,521 |
| Sunovion Pharmaceuticals Inc. | 5 | $1,208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 61 | $1,092 |
| Teva Pharmaceuticals USA, Inc. | 29 | $931 |
| Alkermes, Inc. | 24 | $759 |
| Lundbeck LLC | 25 | $646 |
| Otsuka America Pharmaceutical, Inc. | 24 | $523 |
| Axsome Therapeutics, Inc. | 22 | $497 |
| Vanda Pharmaceuticals Inc. | 18 | $276 |
| E.r. Squibb & Sons, L.L.C. | 10 | $261 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Neuronetics, Inc. | 2 | $158 |
| Idorsia Pharmaceuticals US Inc | 10 | $154 |
| Sage Therapeutics, LLC | 8 | $133 |
| Brainsway USA Inc | 2 | $87 |
| Corium, LLC | 2 | $39 |
| Tonix Medicines, Inc. | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| Harmony Biosciences LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$51,333
- CAPLYTA$9,876
- VRAYLAR$8,199
- ABILIFY MAINTENA$5,593
- ARISTADA$1,406
- LATUDA$1,175
- ARISTADA INITIO$351
- INGREZZA$349
- REXULTI$250
- INVEGA SUSTENNA$240
- INVEGA TRINZA$240
- INVEGA$137
- AUSTEDO$115
How this compares
$174,328 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 25 | $275,338 |
| RexultiBrexpiprazole | 113 | $181,666 |
| IngrezzaValbenazine Tosylate | 14 | $128,656 |
| VraylarCariprazine Hcl | 59 | $85,665 |
| TrintellixVortioxetine Hydrobromide | 104 | $83,573 |
| SpravatoEsketamine Hcl | 23 | $63,774 |
| Invega SustennaPaliperidone Palmitate | 11 | $29,131 |
| Mirtazapine | 1,240 | $23,358 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 941 | $22,802 |
| Duloxetine Hcl | 734 | $18,204 |
| Vilazodone Hcl | 175 | $16,638 |
| Lamotrigine ErLamotrigine | 53 | $10,569 |
| BelsomraSuvorexant | 26 | $10,464 |
| Quetiapine Fumarate | 607 | $9,859 |
| Bupropion XlBupropion Hcl | 390 | $7,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $931 | $275,33825 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $523 | $181,666113 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $66,612 | $128,65614 claims |
| Johnson & JohnsonSpravato, Invega Sustenna | $53,427 | $92,90634 claims |
| AbbVieVraylar | $9,320 | $85,66559 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,092 | $83,573104 claims |
| Eisai Inc.Dayvigo | $25 | $4,72314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in El Paso
- Martin GuerreroEl Paso$2M
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.